Literature DB >> 7468835

Relationship of serum haloperidol levels to clinical response in schizophrenic patients.

J R Magliozzi, L E Hollister, K V Arnold, G M Earle.   

Abstract

The authors treated 16 outpatients and 1 inpatient who had diagnoses of schizophrenia in exacerbation with haloperidol as the sole neuroleptic agent and obtained ratings of psychopathology and serum levels of haloperidol. Improvement in schizophrenic symptoms measured by the Brief Psychiatric Rating Scale was significantly greater in patients who had mean haloperidol serum concentrations in the range of 8-18 ng/ml than in patients whose mean haloperidol serum concentration fell outside this range.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7468835     DOI: 10.1176/ajp.138.3.365

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  17 in total

1.  Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients.

Authors:  Eiji Yukawa; Tsuyoshi Hokazono; Miho Yukawa; Ritsuko Ichimaru; Takako Maki; Kanemitsu Matsunaga; Shigehiro Ohdo; Motoaki Anai; Shun Higuchi; Yoshinobu Goto
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.

Authors:  L T Kucharski; P Alexander; L Tune; J Coyle
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

3.  Human scalp hair as evidence of individual dosage history of haloperidol: method and retrospective study.

Authors:  T Uematsu; R Sato; K Suzuki; S Yamaguchi; M Nakashima
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

5.  Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia.

Authors:  R C Smith; R Baumgartner; A Shvartsburd; G K Ravichandran; G Vroulis; M Mauldin
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 6.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

7.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

8.  Clinical response and plasma haloperidol levels in schizophrenia.

Authors:  M L Mavroidis; D R Kanter; J Hirschowitz; D L Garver
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

Review 9.  Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.

Authors:  R Beresford; A Ward
Journal:  Drugs       Date:  1987-01       Impact factor: 9.546

10.  Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia.

Authors:  A E Balant-Gorgia; R Eisele; L Balant; G Garrone
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.